article Open AccessTop 1% cited

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology · 2019 · Vol. 127(1) · pp. 72–84

Pravin U. Dugel✉(University of Southern California)Adrian Koh(Eye & Retina Surgeons)Yuichiro Ogura(Nagoya City University)Glenn J. JaffeUrsula Schmidt‐Erfurth(Medical University of Vienna)David M. Brown(Retina Consultants of Houston)André Vieira Gomes(Universidade de São Paulo)James Warburton(Novartis (Switzerland))Andreas Weichselberger(Novartis (Switzerland))Frank G. Holz(University of Bonn)

View via DOI Full-text PDF

Abstract

Brolucizumab was noninferior to aflibercept in visual function at Week 48, and >50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing interval through Week 48. Anatomic outcomes favored brolucizumab over aflibercept. Overall safety with brolucizumab was similar to aflibercept (ClinicalTrials.gov; NCT02307682, NCT02434328).

Retinal Diseases and Treatments Retinal and Optic Conditions Retinal Imaging and AnalysisMedicineMacular degenerationOphthalmology

MeSH terms

AgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleMiddle AgedRecombinant Fusion ProteinsVisual AcuityChoroidal NeovascularizationAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AWet Macular DegenerationIntravitreal Injections